Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects

British Journal of Clinical Pharmacology

Volumn 41, Issue 4, 1996, Pages 299-304

  Graham, S ^a,d   Day, R O ^a,b   Wong, H ^b   Mclachlan, A J ^a   Bergendal, L ^e   Miners, J O ^c   Birkett, D J ^c  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d ROYAL HOBART HOSPITAL   (Australia)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allopurinol; Oxypurinol; Pharmacodynamics; Urate; Xanthine oxidase

Indexed keywords

1 METHYLURIC ACID; 1 METHYLXANTHINE; DRUG METABOLITE; OXIPURINOL; URIC ACID; XANTHINE OXIDASE;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0029995128     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03116.x     Document Type: Article

References (16)

1. Rundles RW. The development of allopurinol. Arch Intern Med 1985; 145: 1492-1503.
2. German DC, Holmes EW. Hyperuricaemia and gout. Med Clinics of North Am 1986; 70: 419-436.
3. Korkoff IH, Meyer RL. Prevention of hyperuricaemia in leukemia and lymphoma. JAMA 1965; 193: 89-94.
4. Day RO, Birkett DJ, Hicks M, Miners JO, Graham GG, Brooks PM. New uses for allopurinol. Drugs 1994; 48: 1-6.
5. Appelbaum SJ, Mayersohn M, Dorr RT, Perrier D. Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. Cancer Chemother Pharmacol 1982; 14: 789.
6. Murell GAC, and Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin Pharmacokin 1986; 11: 343-353.
7. Cameron JS, Simmonds HA. Use and abuse of allopurinol. Br Med J 1987; 294: 1504-1505.
8. Emmerson BT, Gordon RB, Cross M, Thomson DB. Plasma oxypurinol concentrations during allopurinol therapy. Br J Rheumatol 1987; 26: 445-449.
9. Bergmann F, Dikstein S. Studies on uric acid and related compounds. III. Observations on the specificity of mammalian oxidases. J Biol Chem 1956; 223: 765-780.
10. Birkett DJ, Miners JO, Attwood J. Secondary metabolism of theophylline; biotransformation products in man-route of formation of 1-methyluric acid. Br J Clin Pharmacol 1983; 15: 117-119.
11. Day RO, Miners J, Birkett DJ, Graham GG, Whitehead A. Relationship between plasma oxypurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol. Br J Clin Pharmacol 1988; 26: 429-434.
12. Kramer WG, Feldman S. High performance liquid Chromatographic assay for allopurinol and oxypurinol in human plasma. J Chromatogr 1979; 162: 94-97.
13. Yamoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6: 165-175.
14. Birkett DJ, Miners JO, Day RO. 1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect. Br J Clin Pharmacol 1991; 32: 238-241.
15. Day RO, Miners JO, Birkett DJ, Whitehead A, Naidoo D, Hayes J, Savdie E. Allopurinol dosage selection: relationships between dose and plasma oxypurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988; 26: 423-428.
16. Gomeni R, Pineu G, Mentre F. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package. Anticancer Res 1994; 14: 2321-2326.